Mark Iwicki

Chairman of the Board, President & Chief Executive Officer at Kala Pharmaceuticals, Inc.

Mark Iwicki

Mark Iwicki

Chairman of the Board, President & Chief Executive Officer at Kala Pharmaceuticals, Inc.

Career Highlights

Kala Pharmaceuticals, Inc.
Civitas Therapeutics, Inc.
Tarveda Therapeutics, Inc.

RelSci Relationships


Number of Boards






RelSci Relationships are individuals Mark Iwicki likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Managing Partner at RA Capital Management LP /Private equity

Relationship likelihood: Strong

Director, President & Chief Executive Officer at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder & Managing Partner at Lux Capital Group LLC

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Sunovion Pharmaceuticals Europe Ltd.

Relationship likelihood: Strong

Partner at Atlas Venture, Inc.

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Intarcia Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Kala Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Pulmatrix, Inc. (Inactive)

Relationship likelihood: Strong

Co-Founder at Rodin Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Mark Iwicki
Potential Connections via
Relationship Science
Mark Iwicki
Chairman of the Board, President & Chief Executive Officer at Kala Pharmaceuticals, Inc.
Class of 1992

Loyola University Maryland is a Jesuit, Catholic university committed to the educational and spiritual traditions of the Society of Jesus and the development of the whole person. Accordingly, the University inspires students to learn, lead, and serve in a diverse and changing world. At Loyola, this means that the curriculum is rigorous and faculty expectations are high. In addition to academic coursework, the Jesuit mission is carried out through a variety of programs and events sponsored by various University departments, including Campus Ministry and the Center for Community Service and Justice. Loyola aims to lead students, faculty, staff, alumni, and friends forward to pursue an examined life of intellectual, social, and spiritual discernment. In pursuing these goals, Loyola asserts a bold vision: that Loyola University Maryland will be the nation's leading Catholic, comprehensive university. The standards by which we measure that achievement include the enrollment of outstanding students; the creation of a diverse and supportive community; the cultivation of a rigorous intellectual climate which distinctly prepares graduates to succeed in any endeavor they choose to pursue; the scholarly achievements of the faculty; the recognition of academic peers; the intellectual and professional attainments and generosity of spirit of the alumni.

Class of 1989

Founded in 1918, Ball State is a state-assisted residential university in Muncie, Indiana, a midsize Midwestern city one hour northeast of Indianapolis. Ball State is ranked a research university, high research activity by the Carnegie Foundation for the Advancement of Teaching and is accredited by the Higher Learning Commission. Individual programs are accredited by various regional and national organizations. At Ball State, they're more than just educators—they're educational entrepreneurs. Combining top-flight talent with the top-notch resources they have to offer, theirr students and faculty inject endless energy and creativity into what they teach and how they learn. The result—a university The Princeton Review calls one of the best in the Midwest. To fulfill Ball State's mission of fundamentally changing their students, researchers and external partners, they offer comprehensive academic opportunities, including about 180 undergraduate majors and preprofessional programs and more than 100 master's and doctoral degrees. Ball State's programs in architecture, telecommunications, landscape architecture, education, entrepreneurship and online master’s degree in nursing are consistently ranked among the best in the nation. That excellence is only possible because of the quality of Ball State's faculty and their commitment to teaching. More than 90 percent of Ball State's classes are taught by professors. That's almost unheard of at an institution of Ball State's size. Ball State believes that for an educational experience to be successful, it should be just that—an experience. So Ball State has made a unique commitment to immersive learning programs that incorporate research, projects with community partners and capstone experiences into the curriculum. Acting, musical theatre, and telecommunications students participate in talent showcases in New York, Chicago and Los Angeles. Students in Ball State's entrepreneurship program face the ultimate pass or fail test—to graduate, they must pitch a business plan that a panel of experts deems viable. Ball State enrolls about 21,000 students, with more than 17,800 attending on campus. Students come from 48 states, two U.S. territories, about 43 countries, and every Indiana county. Out-of-state students make up about 13 percent of on-campus enrollment, and ethnic minorities comprise about 12 percent. The university enrolls more than 675 international students. Today, Ball State’s entrepreneurial spirit continues to shine through numerous expansions and additions of degree offerings, technological resources, immersive learning opportunities, community outreach projects, and state-of-the-art facilities. These investments are preparing bright students to take advantage of current and emerging job opportunities, meet society’s most pressing needs and serve the communities in which they will live and work.

Career History
President & Chief Executive Officer
2007 - 2012

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions. Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.

Vice President & Head-Cardiovascular Business Unit
1998 - 2007

Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom.

President & Chief Executive Officer

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Boards & Committees
Chairman, Board of Directors
2020 - Current

Q32 Bio develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA.

Chairman, Board of Directors
2018 - Current

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Member, Board of Directors
2016 - Current

Oxeia Biopharmaceuticals, Inc. is a private company headquartered in San Diego, CA, that manufactures pharmaceutical products. It was founded by Amit Dilip Munshi. Michael Wyand has been the CEO of the firm since 2017.The company says this about itself: Oxeia Biopharmaceuticals, Inc. is a privately held clinical stage bio technology company headquartered in San Diego, CA. The company is focused on developing treatments for concussions and other acute neurotrauma conditions. Oxeia’s lead program, OXE-103, uniquely targets the metabolic dysfunction and subsequent neurotrauma underlying acute concussion pathophysiology. Oxeia anticipates initiating Phase 2 studies for OXE-103 in concussion and additional neurological indications in early 2018. The program has maintained a strong safety profile across nine previous clinical studies totaling 345 patients.


Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Political Donations

Representative from Massachusetts's 2nd Congressional District

Details Hidden

Kala Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Kala Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Civitas Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Mark Iwicki. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Mark Iwicki's profile does not indicate a business or promotional relationship of any kind between RelSci and Mark Iwicki.